Propylaminopropylacetat | 38825-84-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Propylaminopropylacetat
• 英文别名: 3-(Propylamino)propyl acetate；3-(propylamino)propyl acetate
• CAS: 38825-84-2
• 化学式: C₈H₁₇NO₂
• 分子量: 159.228
• InChiKey: FVTQUNJIJOUJRR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  11
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  Propylaminopropylacetat 在 sodium hydroxide 作用下， 生成 3-丙基氨基丙-1-醇
  参考文献：
  名称：

  丙磺舒的代谢产物。化学，物理和药理研究。

  摘要：

  DOI：

  10.1021/jm00277a004
• 作为产物：
  描述：

  正丙胺 、 乙酰氯 、 3-氯-1-丙醇 生成 Propylaminopropylacetat
  参考文献：
  名称：

  丙磺舒的代谢产物。化学，物理和药理研究。

  摘要：

  DOI：

  10.1021/jm00277a004

文献信息

• PROBENECID FOR TREATING CORONAVIRUS INFECTIONS
  申请人：University of Georgia Research Foundation, Inc.

  公开号：EP3892269A1

  公开（公告）日：2021-10-13

  Compositions and methods of treating a subject for a coronavirus infection are provided. The methods typically include administering the subject an effective amount of probenecid, a metabolite or analog thereof, or a pharmaceutically acceptable salt thereof. The methods can by therapeutic and/or prophylactic. The amount of probenecid or a pharmaceutically acceptable salt thereof can be effective to, for example, reduce viral replication, reduce one or more symptoms of disease, disorder, or illness associated with virus, or a combination thereof. In preferred embodiments, the virus is a Severe acute respiratory syndrome-related coronavirus such as SARS-CoV-2 or SARS-CoV, a Middle East respiratory syndrome-related coronavirus such as MERS-CoV, or a coronavirus that causes the common cold.

  提供了治疗冠状病毒感染受试者的组合物和方法。这些方法通常包括向受试者施用有效量的丙磺舒、其代谢物或类似物或其药学上可接受的盐。这些方法可用于治疗和/或预防。丙磺舒或其药学上可接受的盐的用量可以有效地减少病毒复制，减少与病毒有关的一种或多种疾病、紊乱或病症的症状，或其组合。在优选的实施方案中，病毒是严重急性呼吸系统综合征相关冠状病毒，如SARS-CoV-2或SARS-CoV，中东呼吸系统综合征相关冠状病毒，如MERS-CoV，或引起普通感冒的冠状病毒。
• Methods of using probenecid for treatment of coronavirus infections
  申请人：University of Georgia Research Foundation, Inc.

  公开号：US11116737B1

  公开（公告）日：2021-09-14

  Compositions and methods of treating a subject for a coronavirus infection are provided. The methods typically include administering the subject an effective amount of probenecid, a metabolite or analog thereof, or a pharmaceutically acceptable salt thereof. The methods can by therapeutic and/or prophylactic. The amount of probenecid or a pharmaceutically acceptable salt thereof can be effective to, for example, reduce viral replication, reduce one or more symptoms of disease, disorder, or illness associated with virus, or a combination thereof. In preferred embodiments, the virus is a Severe acute respiratory syndrome-related coronavirus such as SARS-CoV-2 or SARS-CoV, a Middle East respiratory syndrome-related coronavirus such as MERS-CoV, or a coronavirus that causes the common cold.

  提供了治疗冠状病毒感染受试者的组合物和方法。这些方法通常包括向受试者施用有效量的丙磺舒、其代谢物或类似物或其药学上可接受的盐。这些方法可用于治疗和/或预防。丙磺舒或其药学上可接受的盐的用量可以有效地减少病毒复制，减少与病毒有关的一种或多种疾病、紊乱或病症的症状，或其组合。在优选的实施方案中，病毒是严重急性呼吸系统综合征相关冠状病毒，如SARS-CoV-2或SARS-CoV，中东呼吸系统综合征相关冠状病毒，如MERS-CoV，或引起普通感冒的冠状病毒。
• METHODS OF USING PROBENECID FOR TREATMENT OF CORONAVIRUS INFECTIONS
  申请人：University of Georgia Research Foundation, Inc.

  公开号：US20210393564A1

  公开（公告）日：2021-12-23

  Compositions and methods of treating a subject for a coronavirus infection are provided. The methods typically include administering the subject an effective amount of probenecid, a metabolite or analog thereof, or a pharmaceutically acceptable salt thereof. The methods can by therapeutic and/or prophylactic. The amount of probenecid or a pharmaceutically acceptable salt thereof can be effective to, for example, reduce viral replication, reduce one or more symptoms of disease, disorder, or illness associated with virus, or a combination thereof. In preferred embodiments, the virus is a Severe acute respiratory syndrome-related coronavirus such as SARS-CoV-2 or SARS-CoV, a Middle East respiratory syndrome-related coronavirus such as MERS-CoV, or a coronavirus that causes the common cold.
• Metabolites of probenecid. Chemical, physical, and pharmacological studies
  作者：Z. H. Israili、J. M. Perel、R. F. Cunningham、P. G. Dayton、T. F. Yu、A. B. Gutman、K. R. Long、R. C. Long、J. H. Goldstein

  DOI：10.1021/jm00277a004

  日期：1972.7